Homeopathic Drug Proving Trial (HAMSV)
Status and phase
Conditions
Treatments
Details and patient eligibility
About
The main aim of the study is to determine whether a homeopathic drug in the potency C12 provokes more characteristic homeopathic proving symptoms after three weeks compared to a placebo in healthy volunteers.
Secondary aims are to develop and to test a qualitative analysis methodology on which to base a definition for drug-specific (characteristic) symptoms and to compile a profile of characteristic homeopathic proving symptoms of the drug being trialled for therapeutic purposes.
This study protocol adapts the traditional homeopathic drug proving methodology to a modern clinical trial design.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Medical doctors or medical students
- Not being treated for any acute or chronic diseases on the day of inclusion
- Written informed consent.
Exclusion criteria
- Pregnant women or nursing mothers
- Homeopathic treatment over the previous six weeks
- Participation in another clinical trial during the last six months
- Anyone with a personal or professional dependence on the study physician or sponsor
- Anyone who has been placed in hospital or other institution by authorities or decree
Trial design
29 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal